MedTrace Logo

A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors

NCT06452160 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 103

Last updated 2024-08-09

No results posted yet for this study

Summary

The goal of this open-label, dose escalation and dose expansion Phase I clinical trial is to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of BGC515 administered once daily in 3 weeks cycles in solid tumor patients.

Conditions

Interventions

DRUG

BGC515

Capsules for oral administration

Sponsors & Collaborators

  • BridGene Biosciences Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-27
Primary Completion
2027-06-30
Completion
2027-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06452160 on ClinicalTrials.gov